Premium
Mortality results in GUSTO
Author(s) -
Werf Frans
Publication year - 1993
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1993.tb04749.x
Subject(s) - medicine , streptokinase , heparin , tissue plasminogen activator , regimen , surgery , thrombolysis , t plasminogen activator , anesthesia , cardiology , myocardial infarction
The mortality results for the four arms of the GUSTO trial are presented. The 30 day mortality results were as follows: streptokinase (SK) and subcutaneous heparin (n=9796), 7.2%, SKand intravenous heparin (n=10,377) 7.4%, accelerated tissue plasminogen activator (t‐PA) and intravenous heparin (n = 110,344) 6.3%, and combined SK and t‐PA (n=10,328) 7.9%. This is a relative risk reduction of 14% for the accelerated t‐PA regimen compared with the two SK regimens equivalent to an absolute risk reduction of ten lives saved per 1000 patients treated. Predefined subgroups who showed a greater benefit with t‐PA versus SK were patients under the age of 75, anterior infarct location and those treated within four hours of onset of symptoms. (Aust NZ J Med 1993; 23: 000‐000.)